A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis.

Kathy WeiselNicola ScottScott BergerSusanne WangKurt BrownMarcy PowellMatthijs BroerClarissa WattsDebra J TompsonSusan W BurrissSimon HawkinsKathy Abbott BannerPaul Peter Tak

Published in: BMJ open gastroenterology (2021)

NCT02903966.

Keyphrases

ulcerative colitis
double blind
clinical trial
placebo controlled
open label
signaling pathway
pi k akt
study protocol
cell proliferation